BACKGROUND: Young patients are thought to develop gastric carcinomas with a molecular genetic profile that is distinct from that of gastric carcinomas occurring at a later age. The aim of this study was to compare the clinicopathological features and expression patterns of the markers E-cadherin and beta-catenin, and mucins (MUC1, MUC2, MUC5AC, and MUC6) in young and older patients. METHODS: The clinicopathological features and overall survival data of 62 young patients (age <or=40 years) with gastric cancer were retrospectively reviewed from hospital records and compared with the data for 453 older patients (age >40 years). A tissue microarray method and immunohistochemistry were used in order to analyze marker expression in paraffin-embedded tissue blocks obtained from both groups. RESULTS: The young group presented a higher percentage of diffuse-type tumors in comparison to the older group (P<0.01). The rates of positivity for E-cadherin and beta-catenin membranous expression patterns and mucin (MUC2, MUC5AC and MUC6) positivity were higher in the young group (P<0.01). Although young patients showed a lower frequency of alterations in marker expression and had significantly better survival rates than the older patients, neither age nor the marker expression pattern were found to be independent prognostic factors of survival. Only stage, tumor size, and tumor location persisted as prognostic factors for patients with gastric cancer. CONCLUSION: Biological markers of cellular adhesion and gastric differentiation were differently expressed in young and older patients. Our findings support the hypothesis that young patients develop carcinomas with a different genetic pathway compared to the pathway of tumors occurring at a later age, and we suggest further investigations to assess the prognostic relevance of the markers to specific subgroups.
BACKGROUND: Young patients are thought to develop gastric carcinomas with a molecular genetic profile that is distinct from that of gastric carcinomas occurring at a later age. The aim of this study was to compare the clinicopathological features and expression patterns of the markers E-cadherin and beta-catenin, and mucins (MUC1, MUC2, MUC5AC, and MUC6) in young and older patients. METHODS: The clinicopathological features and overall survival data of 62 young patients (age <or=40 years) with gastric cancer were retrospectively reviewed from hospital records and compared with the data for 453 older patients (age >40 years). A tissue microarray method and immunohistochemistry were used in order to analyze marker expression in paraffin-embedded tissue blocks obtained from both groups. RESULTS: The young group presented a higher percentage of diffuse-type tumors in comparison to the older group (P<0.01). The rates of positivity for E-cadherin and beta-catenin membranous expression patterns and mucin (MUC2, MUC5AC and MUC6) positivity were higher in the young group (P<0.01). Although young patients showed a lower frequency of alterations in marker expression and had significantly better survival rates than the older patients, neither age nor the marker expression pattern were found to be independent prognostic factors of survival. Only stage, tumor size, and tumor location persisted as prognostic factors for patients with gastric cancer. CONCLUSION: Biological markers of cellular adhesion and gastric differentiation were differently expressed in young and older patients. Our findings support the hypothesis that young patients develop carcinomas with a different genetic pathway compared to the pathway of tumors occurring at a later age, and we suggest further investigations to assess the prognostic relevance of the markers to specific subgroups.
Authors: Stephan E Baldus; Stefan P Mönig; Verena Arkenau; Franz-Georg Hanisch; Paul M Schneider; Juergen Thiele; Arnulf H Hölscher; Hans P Dienes Journal: Ann Surg Oncol Date: 2002-11 Impact factor: 5.344
Authors: Gianpaolo Suriano; David Mulholland; Olivier de Wever; Paulo Ferreira; Ana Rita Mateus; Eric Bruyneel; Colleen C Nelson; Marc M Mareel; Jun Yokota; David Huntsman; Raquel Seruca Journal: Oncogene Date: 2003-08-28 Impact factor: 9.867
Authors: S A Gayther; K L Gorringe; S J Ramus; D Huntsman; F Roviello; N Grehan; J C Machado; E Pinto; R Seruca; K Halling; P MacLeod; S M Powell; C E Jackson; B A Ponder; C Caldas Journal: Cancer Res Date: 1998-09-15 Impact factor: 12.701
Authors: Jung-Soo Pyo; Young San Ko; Guhyun Kang; Dong-Hoon Kim; Woo Ho Kim; Byung Lan Lee; Jin Hee Sohn Journal: J Cancer Res Clin Oncol Date: 2014-12-05 Impact factor: 4.553
Authors: Sebastian Dwertmann Rico; Moritz Mahnken; Franziska Büscheck; David Dum; Andreas M Luebke; Martina Kluth; Claudia Hube-Magg; Andrea Hinsch; Doris Höflmayer; Christina Möller-Koop; Christoph Fraune; Katharina Möller; Anne Menz; Christian Bernreuther; Frank Jacobsen; Patrick Lebok; Till S Clauditz; Guido Sauter; Ria Uhlig; Waldemar Wilczak; Ronald Simon; Stefan Steurer; Sarah Minner; Eike Burandt; Till Krech; Andreas H Marx Journal: Technol Cancer Res Treat Date: 2021 Jan-Dec